A subsidiary of Medicenna Therapeutics Corp (CVE:MDNA) has treated the first patient in its Phase 2b clinical trial of its lead candidate to treat the most common and uniformly fatal form of brain cancer.
Immunotherapy MDNA55 is the subsidiary's lead candidate and is for recurrent glioblastoma (rGB).
"Dosing the first patient in this clinical trial is a significant milestone for the company as we look to build upon the promising results from earlier studies with MDNA55," said Dr Fahar Merchant, chairman and chief executive of Medicenna.
"We are pleased to be working with leading neuro-surgical centers in the US as we explore the benefits of MDNA55 for the treatment of rGB and other types of brain cancer."
The study is a multi-center, single-arm, open-label, Phase 2 investigation and will enroll around 43 adult patients with glioblastoma who have progressed or recurred following previous therapy.
Top line results expected in 2018..
The study will be conducted in around ten US sites. Patient enrolment is expected to be completed before the end of 2017 with top-line results anticipated in the first half of 2018.
MDNA55 has received 'fast track designation' from the FDA and orphan drug status from both the FDA and EMA.
Earlier results from three Phase 1 and 2a clinical trials in 66 patients with glioblastoma showed potent anti-tumor effects without drug-related systemic toxicity in the majority of patients.
Shares added 1.79% in early deals at $2.85.